Genmab A/S Q2 2026 Earnings Recap

The stock rose 6.8% as investors responded positively to broad revenue growth driven by strong commercial performance and encouraging late-stage pipeline developments, notably multiple Phase III readouts on track for H2 26 and new indications advancing for petosemtamab.

Key Takeaways

• Total revenue grew 25% year-over-year, supported by momentum across the portfolio despite strategic investments in late-stage pipeline and integration activities.
• Proprietary portfolio sales surged 37%, with EPKINLY sales reaching $312 million—up 48% year-over-year and 28% sequentially—reflecting solid commercial execution globally.
• Positive Phase III EPCORE DLBCL-4 topline results demonstrated meaningful improvement in progression-free survival, reinforcing the clinical versatility of epcoritamab combinations.
• Petosemtamab is advancing with two new Phase III trials initiated in colorectal cancer, complementing ongoing head and neck cancer studies and expanding its multi-indication potential.
• Multiple critical late-stage data readouts—Rina-S ovarian cancer datasets, petosemtamab colorectal studies, and EPKINLY EPCORE DLBCL-2 interim analysis—are expected in Q4 26, positioning the company for potential approvals and launches in 2027.